C difficile Awareness Month: Breakthroughs and Setbacks

November is Clostridioides difficile (C diff) Awareness Month.

“Usually for antibiotic awareness you have a week,” said Dr. Teena Chopra, “But for C diff a whole month has been dedicated, for a reason.”

Each year, this Gram-positive, highly infectious and resilient bacterium casuses an estimated half a millon infections and a billion dollars in healthcare-related costs in the US alone.

To raise awareness of the high prevalence and mortality of C diff, as well as the most promising therapies, we're recapping our most relevant C diff coverage from the past month.

C difficile, Antimicrobials, and the Patients Most Affected

In the latest episode of the Contagion Community podcast, Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.

New Therapeutic Offers Promise for Recurrent C Diff Infection

An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.

CDI Biotherapeutic RBX2660 Outperforms Placebo in Phase 3 Trial

The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.

By Raising Awareness of C diff, Foundation Hopes to Minimize Risk

The Peggy Lillis Foundation hopes to use the month to increase the public’s awareness of the dangers of the C difficile infection.

FDA PDUFA Date Set for C diff Drug, SER-109

The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.